Nasdaq
$440.51▲ 0.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $237.75BShares out 5.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 9.4After-hours26.09.05 07:523Ownership#●●●
AMGEN INC
Amgen Inc. executive Thomas Dittrich has filed a Power of Attorney to facilitate compliance with Section 16(a) of the Securities Exchange Act. This grants designated attorneys-in-fact the authority to prepare and submit Forms 3, 4, and 5, along with related EDGAR filings, on his behalf.…more
$440.51+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.13Regular26.08.14 00:14144Ownership
AMGEN INC
Rachna Khosla, an executive at Amgen Inc., has filed an SEC Form 144 to report the proposed sale of company shares. This filing formally declares the intent to sell existing holdings of Amgen stock in the open market.…more
$440.51+0.29%vs prev closeView filingShare - 8.13Overnight26.08.13 09:044Ownership
AMGEN INC
Amgen Inc. insider Matthew C. Busch reported a change in beneficial ownership of securities effective August 7, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's equity holdings.…more
$440.51+0.29%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoRegular26.10.21 01:51Bullish#●●●#●●●#●●●
AstraZeneca and Amgen Report Positive Phase 3 Results for Tezspire in EoE…more
AstraZeneca and Amgen's Tezspire met primary endpoints in a Phase 3 trial for eosinophilic esophagitis, showing significant improvements in remission and swallowing symptoms. The positive data supports the potential expansion of the drug's therapeutic use beyond its current indications.…more
$440.51+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.20 22:06
●●●●●●●● ●●●●● ●●●●●●
AstraZeneca and Amgen's TEZSPIRE met all co-primary endpoints in a Phase III trial for eosinophilic esophagitis, demonstrating significant clinical improvements. The results suggest a potential new treatment option for patients who struggle to manage symptoms with current standard therapies.…more
$440.51+0.29%vs prev closeShareBenzinga - 9.22Pre-market26.09.22 22:02
●●●●●●●● ●●●●● ●●●●●●
Amgen announced that its Phase 3 OASIZ 301 trial for dazodalibep successfully met its primary endpoint in treating Sjögren's disease. The treatment demonstrated statistically significant improvements in systemic disease activity through 48 weeks.…more
$440.51+0.29%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report